New research indicates that people who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain lost weight much more quickly than those who stop conventional diet and exercise regimens.
Published data in a prominent medical journal demonstrates that while overweight people often shed a large proportion of their total mass while on the medication, the mass comes back at an estimated rate of 0.8 kg per month after stopping.
"Individuals buying such medications must be aware of the risk of quick weight regain when the treatment is stopped," warns lead investigator Dr. Susan Jebb.
This pace of regain means a reversion to starting mass within about a year and a half.
Comparing Approaches
The research, which looked at 37 of studies involving over 9,000 of participants, contrasted the results of these new drugs with older methods.
Scientists point out that people who lose weight through diet and exercise typically have a slower creep back—perhaps 0.1 kg a month—post-intervention.
The Reason for the Quick Regain
Doctors believe the way of the drugs is key to understanding the amplified weight return.
The injections copy a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Artificially providing the hormone concentrations far above than normal may cause the system to produce less of its endogenous hormone, and may also lessen sensitivity to its effects," explained Dr. Adam Collins, a nutrition expert.
"Withdrawal of this hormone supplement leads to appetite is uncontrolled, making binge eating a significant risk."
A Lifelong Disease?
Health authorities recommend the jabs for people with obesity-related health risks, accompanied by recommended diet and exercise modifications.
Many experts contend that, due to the likelihood of weight regain, the therapy is often ongoing.
This opinion is supported by drug manufacturers, who note that the findings "highlight the chronic character of obesity," similar to managing diseases like high blood pressure.
User Experiences
Individuals who have discontinued the medication report a sudden return of appetite.
"I experienced a switch activating and I was suddenly extremely hungry," recalled an individual.
This difficulty is worsened if individuals have not developed lasting dietary or behavioural modifications during therapy.
Significant Adoption
Survey data indicate that millions of people in the UK have tried these injections in the past year, with demand remaining high.
- Adoption is greater among women than males.
- The 40s and 50s demographic shows the highest level of interest.
- Many obtain the medications through private prescriptions rather than public health services.
In conclusion, researchers emphasize that while the jabs are potent tools for weight loss, they are not a standalone cure and long-term success relies on combined behavioural management.
